文献速递淋巴瘤

Urelumab单药或联合利妥昔单抗治疗复发或难治性B细胞淋巴瘤的1期研究

Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma.
PubMed 文献 · Am J Hematol · 2020-02-29

两项1期研究评估了CD137激动剂urelumab单药或联合利妥昔单抗在复发/难治性B细胞淋巴瘤患者中的安全性和疗效。最大耐受剂量为0.1 mg/kg或8 mg每3周。联合治疗未显示优于利妥昔单抗单药或现有标准治疗的临床活性。

要点

  • Urelumab单药或联合利妥昔单抗在B细胞淋巴瘤中安全性可控。
  • 联合治疗未增强临床活性,不优于利妥昔单抗单药或现有标准治疗。
  • 持久缓解多见于超过最大耐受剂量的患者。

核心结论

  • Urelumab单药或联合利妥昔单抗在B细胞淋巴瘤中安全性可控,但联合治疗未增强相对于利妥昔单抗单药或现有标准治疗的临床活性。

研究设计与样本

  • 纳入复发或难治性DLBCL、FL及其他B细胞淋巴瘤患者。

主要发现

  • 单药组客观缓解率/疾病控制率:DLBCL 6%/19%(n=31),FL 12%/35%(n=17),其他B细胞淋巴瘤17%/42%(n=12)。
  • 联合组客观缓解率/疾病控制率:DLBCL 10%/24%(n=29),FL 35%/71%(n=17)。
  • 治疗相关不良事件发生率:单药组52%(3/4级15%),联合组72%(3/4级28%)。
  • 3例因不良事件终止治疗:单药组3级AST升高和4级急性肝炎,联合组1例脓毒症综合征死亡。
  • 在重度预处理患者中观察到持久缓解,但许多缓解出现在超过最大耐受剂量的剂量下。

关键数值与推荐

  • Urelumab最大耐受剂量确定为0.1 mg/kg或8 mg每3周(在0.3 mg/kg发生潜在药物性肝损伤事件后)。
  • 单药组给药方案:0.3 mg/kg IV Q3W、8 mg IV Q3W或8 mg IV Q6W。
  • 联合组urelumab剂量:0.1 mg/kg、0.3 mg/kg或8 mg IV Q3W,联合利妥昔单抗375 mg/m2 IV QW。

临床怎么用

  • Urelumab单药或联合利妥昔单抗在B细胞淋巴瘤中安全性可控,但联合治疗未显示优于利妥昔单抗单药或现有标准治疗的临床活性。

局限性

  • 持久缓解多出现在超过最大耐受剂量的剂量下。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity in preclinical models, and may enhance cytotoxic activity of rituximab. Here we report results in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other B-cell lymphomas, in phase 1 studies evaluating urelumab alone (NCT01471210) or combined with rituximab (NCT01775631). Sixty patients received urelumab (0.3 mg/kg IV Q3W, 8 mg IV Q3W, or 8 mg IV Q6W); 46 received urelumab (0.1 mg/kg, 0.3 mg/kg, or 8 mg IV Q3W) plus rituximab 375 mg/m2 IV QW. The maximum tolerated dose (MTD) of urelumab was determined to be 0.1 mg/kg or 8 mg Q3W after a single event of potential drug-induced liver injury occurred with urelumab 0.3 mg/kg. Treatment-related AEs were reported in 52% (urelumab: grade 3/4, 15%) and 72% (urelumab + rituximab: grade 3/4, 28%); three led to discontinuation (grade 3 increased AST, grade 4 acute hepatitis [urelumab]; one death from sepsis syndrome [urelumab plus rituximab]). Objective response rates/disease control rates were 6%/19% (DLBCL, n = 31), 12%/35% (FL, n = 17), and 17%/42% (other B-cell lymphomas, n = 12) with urelumab and 10%/24% (DLBCL, n = 29) and 35%/71% (FL, n = 17) with urelumab plus rituximab. Durable remissions in heavily pretreated patients were achieved; however, many were observed at doses exceeding the MTD. These data show that urelumab alone or in combination with rituximab demonstrated manageable safety in B-cell lymphoma, but the combination did not enhance clinical activity relative to rituximab alone or other current standard of care.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Timmerman J, Herbaux C, Ribrag V, et al. Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. Am J Hematol. 2020. PMID: 32052473. doi:10.1002/ajh.25757

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。